Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Sucampo Pharma Inc (SCMP)

Sucampo Pharma Inc (SCMP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Sucampo Pharma Inc 805 King Farm Boulevard Suite 550 Rockville MD 20850 USA

www.sucampo.com P: 301-961-3400

Description:

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products - AMITIZA, its lead product, and RESCULA - and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.

Key Statistics

Overview:

Market Capitalization, $K 849,060
Shares Outstanding, K 47,170
Annual Sales, $ 230,060 K
Annual Net Income, $ 18,490 K
Last Quarter Sales, $ 61,270 K
Last Quarter Net Income, $ 10,370 K
60-Month Beta 1.38
% of Insider Shareholders 4.13%
% of Institutional Shareholders 67.09%

Growth:

1-Year Return 56.96%
3-Year Return 19.84%
5-Year Return 246.15%
5-Year Revenue Growth 320.12%
5-Year Earnings Growth -355.93%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.27 on 11/01/17
Next Earnings Date 03/14/18
Earnings Per Share ttm 1.46
EPS Growth vs. Prev Qtr -3.57%
EPS Growth vs. Prev Year -3.57%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

SCMP Ratios

Ratio
Price/Earnings ttm 12.33
Price/Earnings forward 15.17
Price/Earnings to Growth 5.06
Return-on-Equity % 74.58%
Return-on-Assets % 16.85%
Profit Margin % 8.04%
Debt/Equity N/A
Price/Sales 3.39
Price/Cash Flow 7.47
Price/Book 21.18
Book Value/Share 0.85
Interest Coverage 6.96
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar